Abstract: The present application provides a semiconductor device and a manufacturing method thereof and a memory system. The manufacturing method of the semiconductor device includes: forming a dielectric layer on a stack layer, wherein memory channel structures penetrating through the stack layer along a first direction are disposed in the stack layer, and the first direction is parallel to a stacking direction of the stack layer; forming a plurality of openings penetrating through the dielectric layer along the first direction, with the rest of the dielectric layer forming top selective gate cut lines, wherein the plurality of openings are arranged as being spaced apart along a second direction, one of the top selective gate cut lines is located between two adjacent ones of the openings in the second direction, and the first direction intersects the second direction; and forming a top selective gate layer in the plurality of openings.

Abstract: The disclosure provides a compound of formula (I) and pharmaceutical compositions thereof. The compound of formula (I) of the present disclosure can be used as a degradation agent of cyclin K (CyclinK protein), and can be used to prevent or treat diseases related to CyclinK protein.

Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.

Abstract: The invention provides a heat-storage medium conveying system for a solar-thermal power plant. The system includes a high-level tank subsystem including a high-level tank used to store the heat-storage medium. The system further includes a heat-storage medium transport subsystem. The high-level tank subsystem is connected with the heat-storage medium transport subsystem. The heat-storage medium transport subsystem includes a low-level tank. A mounting height of the low-level tank is lower than that of the high-level tank. A volume of the low-level tank is smaller than a volume of the high-level tank. The heat-storage medium can enter the low-level tank from the high-level tank partially or completely by its own gravity. The low-level tank is provided with a conveying pump, and the heat-storage medium is pumped out of the low-level tank through the conveying pump.

Abstract: A motor control system includes a main control unit, a power supply unit, and a driving unit. The main control unit obtains sampling data of a motor and a power supply signal from the driving unit, generates a motor control signal according to the sampling data, and outputs a safety enable signal when determining that motor drive is abnormal according to the sampling data or when determining that power supply to the driving unit is abnormal according to the power supply signal. The power supply unit supplies power to the main control unit, monitors a state of the main control unit, and outputs a safety cut-off signal when the power supply unit or the main control unit is abnormal. The driving unit drives the motor according to the motor control signal, and switches to a safe path when receiving any one of the safety enable or safety cut-off signal.

Abstract: Novel, antibody-based binding agents derived from camelid VHH and human immunoglobulins are described. These binding agents recognize and bind with specificity to Clostridium difficile toxin A and/or toxin B and in some cases exhibit toxin neutralizing activity. These binding agents can be used to treat or prevent primary and recurrent CDI. The binding agents include humanized VHH peptide monomers, linked groups of humanized VHH peptide monomers, humanized VHH peptide monomers joined to antibody Fc domains, and humanized VHH peptide monomers joined to IgG antibodies.

Abstract: The present disclosure relates to a device, method and system for calculating, estimating, or monitoring the blood pressure of a subject. At least one processor, when executing instructions, may perform one or more of the following operations. A first signal representing heart activity of the subject may be received. A second signal representing time-varying information on at least one pulse wave of the subject may be received. A first feature in the first signal may be identified. A second feature in the second signal may be identified. A pulse transit time based on a difference between the first feature and the second feature may be computed. The blood pressure of the subject may be calculated according to a first model based on the computed pulse transit time and a first set of calibration values, the first set of calibration values relating to the subject.

Abstract: A combination therapy for treating PIK3CA-mutated cancer, comprising administering a PI3K inhibitor, a prostaglandin receptor (PGE2) inhibitor, and a PD-1 inhibitor to a subject in need thereof. The anti-tumor activity brought about by a three-drug combination method is significantly superior to that brought about by a two-drug combination method of the PI3K inhibitor and the PD-1 inhibitor, and the prostaglandin receptor (PGE2) and the PD-1 inhibitor.

Abstract: The disclosure relates to engineered strains of yeast that express a therapeutic polypeptide(s) and/or comprise a nucleic acid encoding a therapeutic polypeptide(s), as well as methods and uses for the same.

Abstract: Embodiments relate to the technical field of waste collection, in particular to waste collection equipment, which includes a temporary storage tank, a pressing tank and a pressing mechanism; the temporary storage tank is configured for receiving and temporarily storing wastes produced by die cutting equipment; the pressing tank is configured for carrying the wastes in the temporary storage tank; the pressing mechanism is configured for compressing the wastes in the pressing tank; the temporary storage tank is provided with a first blanking port, which is configured for communicating the temporary storage tank with the pressing tank; the first blanking port is provided with a first valve; and the first valve is configured for opening or closing the first blanking port to control whether the temporary storage tank discharges the wastes.

Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.

Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.

Abstract: The present application provides pyrrolotriazine compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.

Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.

Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.

Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.